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Abstract: Non-selective and cyclooxygenase-2 (COX-2) selective non-steroidal anti-
inﬂ  ammatory drugs (NSAIDs) have been the mainstay of treatment for musculoskeletal pain 
of moderate intensity. However, in addition to gastrointestinal and renal toxicity, an increased 
cardiovascular risk may be a class effect for all NSAIDs. Despite these safety risks and the 
acknowledged ceiling effect of NSAIDs, many doctors still use them to treat moderate, mostly 
musculoskeletal pain. Recent guidelines for treating osteoarthritis and low back pain, issued by 
numerous professional medical societies, recommend NSAIDs and COX-2 inhibitors only in 
strictly deﬁ  ned circumstances, at the lowest effective dose and for the shortest possible period 
of time. These recent guidelines bring more focus to the usage of paracetamol and opioids. But 
opioids still remain under-utilized, although they are effective with minimal organ toxicity. In 
this setting, the atypical, centrally acting analgesic tramadol offers important beneﬁ  ts. Its multi-
modal effect results from a dual mode of action, ie, opioid and monoaminergic mechanisms, 
with efﬁ  cacy in both nociceptive and neuropathic pain. Moreover, fewer instances of side effects 
such as constipation, respiratory depression, and sedation occur than with traditional opioids, 
and tramadol has been prescribed for 30 years for a broad range of indications. Tramadol is 
now regarded as the ﬁ  rst-line analgesic for many musculoskeletal indications. In conclusion, it 
is recommended to better implement the more recent guidelines focusing on pain management 
and consider the role of tramadol in musculoskeletal pain treatment strategies.
Keywords: musculoskeletal pain, osteoarthritis, chronic low back pain, opioids, NSAIDs, 
coxibs, tramadol, multi-modal
Introduction
The focus of this article is the current treatment of musculoskeletal pain – a therapeutic 
area that has seen many changes over the past few years. In 2002, American Pain Society 
guidelines for the management of osteoarthritis recommended cyclooxygenase-2 
(COX-2) selective inhibitors and non-selective non-steroidal anti-inﬂ  ammatory drugs 
(NSAIDs) (Simon et al 2002). However, the discovery that rofecoxib was linked to 
an increased incidence of myocardial infarction and stroke led to dramatic changes 
(Graham 2006). At ﬁ  rst it was thought that increased cardiovascular risk might be a 
class effect of COX-2 inhibitors, but it is now understood that the problem extends 
to the non-selective NSAIDs (Graham et al 2005; Lee et al 2007). The US Food and 
Drug Administration (FDA) has clearly stated that a greater risk of cardiovascular 
events may be a class effect for all NSAIDs (FDA 2005). Although long-term clinical 
trials have not been conducted for most NSAIDs, the FDA concludes from the avail-
able data that their use could increase cardiovascular risk. Moreover, the gastric and 
renal toxicity associated with these agents is well established (Whelton 2000; Dieppe 
et al 2004). This paper reviews the recent guidelines for musculoskeletal pain with an 
emphasis on the role of an atypical opioid, tramadol, as an option.Therapeutics and Clinical Risk Management 2007:3(5) 718
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Current guidelines
Recently, there has been a widespread re-examination of 
the management of musculoskeletal pain. For example, the 
Canadian Consensus Conference suggests that NSAIDs 
should be used with caution in elderly patients, who are at 
greatest risk of gastrointestinal, renal, and cardiovascular 
side effects (Tannenbaum et al 2006). This Conference 
also suggests that elderly patients with osteoarthritis or 
rheumatoid arthritis should be treated in the context of a 
multi-faceted treatment plan that aims to preserve function 
and independence and improve quality of life. This is a good 
and worthwhile concept, but it is necessary to deﬁ  ne exactly 
how it can be achieved.
The European League Against Rheumatism (EULAR) 
has just published guidelines for the management of hip 
osteoarthritis (Zhang et al 2005). Interestingly, these state 
that opioid analgesics are useful alternatives in patients in 
whom NSAIDs – including COX-2 selective inhibitors – are 
contra-indicated, ineffective, and/or poorly tolerated. Nearly 
every set of guidelines that has appeared over the past 2 or 3 
years recognizes that paracetamol and opioids have a more 
signiﬁ  cant role to play in the management of chronic pain.
The European Guidelines for the Management of Chronic 
Non-Speciﬁ  c Low Back Pain (Airakinsen et al 2006) conclude 
there is strong evidence that weak opioids relieve pain and 
disability in the short term in chronic low back pain patients. 
Notably, this is “level A” evidence comprising robust data. 
There is a clear suggestion that clinicians should decrease 
their use of organ-toxic NSAIDs and COX-2 inhibitors, and 
possibly increase the prescription of opioids.
The American Geriatrics Society Panel (AGS) on 
Persistent Pain in Older Persons now considers that for 
many older patients, chronic opioid therapy may have fewer 
life-threatening risks than long-term daily use of NSAIDs 
(AGS 2002). Comparing the organ toxicity of opioids and 
NSAIDs, this is clearly the case.
Choice of opioid
Thus guidelines produced over the past 4 years have shifted 
their emphasis from NSAIDs and COX-2 inhibitors to 
opioids, which clearly makes sense in the context of mus-
culoskeletal pain. However, strong opioids are not always 
required. In this setting it is interesting to consider a drug that 
is not a monomodal opioid – tramadol. A better description 
of this agent is “a atypical centrally acting analgesic”. In 
the central nervous system (CNS), speciﬁ  cally in the dorsal 
horn of the spinal cord, tramadol has a number of effects, 
as illustrated in Figure 1. Where the ﬁ  rst order neuron 
transmits a pain impulse to the second order neuron, which 
in turn relays the information to the brain, tramadol binds 
to some extent to the µ-opioid receptor (its M1 metabolite 
does so to a greater extent) (Grond and Sablotzki 2004); 
this produces some of its analgesic effect and explains why, 
model dependent, around 40% of tramadol analgesia can be 
reversed by opioid antagonists (Raffa et al 1992). In addition, 
the descending pathways responsible for pain relief rely on 
monoaminergic transmission, primarily via noradrenaline 
and serotonin. Here, tramadol binds to the descending 
pathway neurons, inhibiting the re-uptake of noradrenaline 
and serotonin, and accounting for the remaining analgesic 
properties (Desmeules et al 1996). Thus tramadol produces a 
multi-modal effect with its dual mechanism of action (Raffa 
and Friderichs 1996).
Traditional opioids produce analgesia but also cause consti-
pation, respiratory depression, and sedation, as well as having 
a signiﬁ  cant abuse potential (Vickers et al 1992; Grond et al 
2001; Atluri et al 2003; Cicero et al 2004). It has been clearly 
demonstrated that the combined opioid and monoaminergic 
mechanisms of tramadol can mitigate these adverse effects 
(Richter et al 1985; Preston et al 1991; Epstein et al 2006). 
At the same time efﬁ  cacy can be increased, particularly in 
patients suffering from neuropathic pain, where the enhance-
ment of monoaminergic transmission is beneﬁ  cial (Harati et 
al 1998; Sindrup et al 1999; Christoph et al 2007). Other side 
effects – dizziness, nausea, vomiting and sweating – remain at 
a similar level to traditional opioids (Allan et al 2001; Grond 
et al 2001). These differences are summarized in Table 1.
The efﬁ  cacy and safety of tramadol in patients with 
musculoskeletal pain are both very well documented 
(see Table 2), and these have had an impact on treatment. 
A number of international guidelines now specifically 
recommend tramadol – not just weak opioids. The American 
Pain Society suggests that tramadol can be used alone, or in 
combination with paracetamol or NSAIDs, for therapy at any 
stage during the treatment of a patient with osteoarthritis. The 
American College of Rheumatology states that the efﬁ  cacy 
of tramadol has been found to be comparable with that of 
ibuprofen in patients with hip and knee osteoarthritis, and 
has proven useful as adjunctive therapy in patients whose 
symptoms are inadequately controlled by NSAIDs (Dalgin 
et al 1997; Roth 1998; Altman et al 2000). The clear impli-
cation is that tramadol may be used instead of an NSAID, 
for example in patients with cardiac or renal complications 
(Whelton 2000; Aronow 2003). If a patient is already 
receiving an NSAID it can be combined with tramadol in 
a multi-modal analgesic approach thereby permitting dose Therapeutics and Clinical Risk Management 2007:3(5) 719
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reduction of the NSAID (Schnitzer et al 1999). For patients 
with chronic low back pain, the previously quoted European 
Guidelines explicitly recommend the use of “weak opioids 
(eg, tramadol)” in patients with non-speciﬁ  c chronic low 
back pain who do not respond to other treatment modalities 
(Airaksinen et al 2006).
Even in conditions where central sensitization is now 
thought to play an important role, there is support for the use 
of tramadol. For example, the Veterans Health Administra-
tion of the US Department of Defence considers tramadol to 
be a therapeutic intervention with some beneﬁ  ts for sufferers 
from ﬁ  bromyalgia (Buckhardt et al 2005). In the long-term 
care of the elderly, the American Medical Directors Associa-
tion says that tramadol is a ﬁ  rst line pharmacological treat-
ment for chronic pain, together with paracetamol, NSAIDs, 
and COX-2 inhibitors (AMDA 2003).
The working group on pain 
management
It is apparent that revised guidelines for pain management are 
needed, and that these will encourage greater prescription of 
opioids and reduced use of NSAIDs and COX-2 inhibitors, 
as well as speciﬁ  cally recommending tramadol. There is 
a Working Group on Pain Management which regularly 
publishes its ﬁ  ndings, including guidelines (Schnitzer 2006) 
(on the Internet at www.painworkinggroup.org). Its recom-
mendations today differ signiﬁ  cantly from those issued by 
others before 2004.
Osteoarthritis patients without particular risk factors 
should receive background analgesia with up to 4 g/day of 
paracetamol. For a short-term ﬂ  are, NSAIDs or the immediate-
release paracetamol–tramadol ﬁ  xed combination tablet should 
be administered. If this does not adequately control the pain 
then immediate release tramadol can be administered. An 
immediate-release strong opioid can be considered if the 
patient still experiences insufﬁ  cient pain relief. For long-term 
pain management, NSAIDs are not recommended. The regi-
men is similar to that for short-term treatment but there are 
advantages to prescribing sustained-release tramadol formula-
tions. These treatment regimens are summarized in Figure 2.
In elderly patients with low back pain who have no par-
ticular risk factors and require long term pain management, 
Serotonergic effect (≈20%) of (+)-tramadol
Noradrenergic effect (≈40%) of (–)-tramadol
Opioid effect (≈40%):
Some effect of (+)-tramadol
More effect by main metabolite M1
Spinal neuron Afferent C-ﬁbres
Endorphin
µ-receptor
Pain transmitter
2 Receptor
Neuron of the
spinothalamic tract
To the
brain Descending
pathway
Serotonin/
Noradrenaline
Pain
message
Figure 1 Synergistic effects of tramadol at the dorsal horn (Collart et al 1993; Raffa and Friderichs 1996).Therapeutics and Clinical Risk Management 2007:3(5) 720
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the working group recommends the use of a weak opioid 
plus paracetamol, or tramadol monotherapy (see Figure 3). 
NSAIDs and COX-2 inhibitors can be prescribed for young 
healthy adults without risk factors, but even the FDA and 
the European Medicines Agency (EMEA 2005) now state 
that the smallest possible dose should be used for the shortest 
possible time. So the paracetamol–tramadol ﬁ  xed combina-
tion tablet or tramadol sustained release may be preferred. 
Thus the achievement of pain management goals such as 
improved functioning, return to work, and a better quality of 
life is based largely on paracetamol and tramadol.
There is a large body of high quality evidence for 
using tramadol as suggested by the working group, par-
ticularly in neuropathic pain. Low back pain often has a 
neuropathic component, which plays a major role in the 
condition of patients referred to chronic pain clinics. One 
recent large scale study found that in an unselected cohort 
of chronic low back pain patients, 37% had predominantly 
neuropathic pain (Freynhagen et al 2006). This is also the 
pain component that is most difﬁ  cult to treat in the general 
practice setting.
Tramadol is increasingly gaining acceptance as it is 
effective against both nociceptive and neuropathic pain. 
There have now been a considerable number of randomized, 
controlled trials, and a Cochrane review, that show a high 
efﬁ  cacy of tramadol in neuropathic pain (Dühmke et al 2004); 
Table 1 Effects of traditional opioids in comparison with tramadol
   Tramadol  in
   comparison  with
   typical  strong  opioids
Analgesic efﬁ  cacy 
–  in nociceptive pain  effective
–  in neuropathic pain  ﬁ  rst line option
–  in mixed pain  effective
Abuse potential  less
Side effects 
– respiratory  depression  less
– constipation  less
– sedation    less
– dizziness  equal
– nausea  equal
– vomiting  equal
– sweating  equal
Table 2 Controlled trials of oral tramadol in patients with chronic musculoskeletal pain
Study  Type of pain  Study  N  Duration  Analgesic drug  Dosage  Analgesic efﬁ  cacy  Adverse
   design        (mg/day)    events
Adler et al 2002  Osteoarthritis  db  279  1 mo  SR tramadol  150–400  SR-T = IR-T  SR-T = IR-T 
         IR  tramadol  150–400
Bird et al 1995  Osteoarthritis  db, co  40  2 × 2 wk  IR tramadol  200  T PE  T < PE
Gorol 1983  Chronic  db  94  1 wk  IR tramadol  prn  T TI/N NR
         Tilidine/naloxone  prn
Jensen and Ginsberg 1994  Osteoarthritis  db, co  264  2 wk  IR tramadol  300  T D T   D
Pavelka et al 1998  Osteoarthritis  db  60  2 × 4 wk  IR tramadol  164  T = DI  T = DI
         Diclofenac  97
Rauck et al 1994  Chronic  db  990  4 wk  IR tramadol  244
         Paracetamol/  1407/140  T  = P/C  T = P/C
         codeine
Roth 1998  Osteoarthritis  db  63  13 d  IR tramadol +  250  T PL NR
         NSAID
         Placebo  +  NSAID
Schnitzer et al 2000  Low back  db  254  4 wk  IR tramadol  200-400  T PL T   PL
         Placebo
Silverﬁ  eld et al 2002  Osteoarthritis  db  308  10 d  IR tramadol/
         paracetamol  150–300/  T/P  PL T/P   PL
         +  NSAID  1300–2600
Sorge and Stadler 1997  Low back  db  205  3 wk   SR tramadol  200  SR-T = IR-T  SR-T = IR-T
Wilder-Smith et al 2001  Osteoarthritis  db  60  1 mo  SR tramadol  200  T DC T  DC
         IR  tramadol  200
         SR  dihydrocodeine  200
Abbreviations: C, codeine; co, crossover; d, days; D, dextropropoxyphene; db, double-blind; DC, dihydrocodeine; DI, diclofenac; IR, immediate release; mo, months; 
N, naloxone; NR, not reported; P, paracetamol; PE, pentazocine; PL, placebo; prn, as needed; SR, sustained-release; T, tramadol; TI, tilidine; wk, weeks;  indicates superior to; = 
indicates equivalent to; < indicates inferior to.Therapeutics and Clinical Risk Management 2007:3(5) 721
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Paracetamol up to 4 g/day
+/- glucosamine
If insufﬁcient
Moderate to Severe OA Pain: Systemic Analgesia
Patients without Particular Risk Factors
Short-term / ﬂare Long-term
Paracetamol/tramadol
Tramadol SR
Strong opioids SR
NSAIDs
Weak opioid comb.
e.g. paracetamol/tramadol
Tramadol IR
Strong opioids IR
Pain Intensity
Moderate
Severe
Figure 2 Recommendations of the working group on pain management for patients with osteoarthritis.
the number needed to treat (NNT) compared with placebo 
to achieve at least 50% pain relief was 3.5 with a number 
needed to harm (NNH) of 7.7. Based on these favorable 
numbers, in the latest evidence-based algorithms for treat-
ing neuropathic pain, tramadol is very high in the sequence 
of drugs that should be used (Dworkin et al 2003; Finnerup 
et al 2005).
Conclusion – the need for change
Many doctors still use NSAIDs and COX-2 inhibitors to 
treat musculoskeletal pain, despite the safety risks and the 
fact that these agents have a ceiling effect, so that continu-
ing to increase the dose only results in a greater incidence 
of adverse events. Also, the inﬂ  ammatory component of 
osteoarthritis pain is minimal (Backonja 2003) – perhaps 
osteoarthrosis would be a more accurate term, so an 
anti-inﬂ  ammatory drug is not needed in these patients, and 
NSAIDs carry the risk of organ toxicity (Singh 2000; Lanas 
et al 2003; Dieppe et al 2004; Laporte et al 2004; Graham 
et al 2005). This was previously believed to be limited to 
the kidney and stomach but is now known to extend to the 
heart and cardiovascular system (Davies et al 2006). Opioids 
are currently under-utilized, although they are known to be 
effective and have minimum organ toxicity – possibly none 
in most settings – even in long-term use (Brown and Stinson 
2004; Raffa 2006). This might be of particular importance 
in the elderly, as they exhibit commonly already impaired 
or reduced organ function (Auret and Schug 2005). Many 
guidelines have changed in the last 4 years, but have not yet 
been implemented in routine clinical practice.
Tramadol is now speciﬁ  cally recommended in muscu-
loskeletal pain guidelines and neuropathic pain guidelines, 
because of its efﬁ  cacy, safety, and tolerability (Dworkin 
et al 2003; Dühmke et al 2004; Finnerup et al 2005). Clearly 
there is no major organ toxicity (Shipton 2000; Raffa 2006), 
and its use necessarily implies an NSAID-sparing effect 
(Schnitzer et al 1999). The improved side effect proﬁ  le over 
traditional opioids is particularly marked in the case of con-
stipation, which is usually the biggest problem with opioid 
use in the elderly. Finally, tramadol has been on the market 
for 30 years and clinical experience now extends to more 
than 5 billion patient treatment days, so the data underlying 
the latest guidelines are extremely robust (IMS Health Inc. 
1994 –2005).Therapeutics and Clinical Risk Management 2007:3(5) 722
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